Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results
Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the...
OTCMKTS: HLBBF
Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF),...
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...